Table of Contents Author Guidelines Submit a Manuscript
AIDS Research and Treatment
Volume 2012, Article ID 703604, 6 pages
http://dx.doi.org/10.1155/2012/703604
Research Article

Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults

1Department of Clinical Pharmacology, University College Hospital and Department of Pharmacology & Therapeutics, College of Medicine, University of Ibadan, Ibadan, Nigeria
2Division of Infectious Diseases & Center for Global Health, Northwestern University Feinberg School of Medicine, Chicago, IL 60614, USA
3Translational Pharmacology Research Core, NYS Center of Excellence in Bioinformatics and Life Sciences, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14203, USA
4Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA 94110, USA
5Department of Obstetrics & Gynecology, University College Hospital, Ibadan, Nigeria
6Department of Obstetrics & Gynecology, College of Medicine, University of Ibadan, Ibadan, Nigeria
7Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
8Department of Pediatrics, College of Medicine, University of Ibadan, Ibadan, Nigeria
9Drug Research Unit, Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, San Francisco, CA 94110, USA

Received 16 October 2011; Accepted 15 December 2011

Academic Editor: Gary Maartens

Copyright © 2012 Fatai A. Fehintola et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, World Malaria Report: 2010, World Health Organization, 2010, http://www.who.int/malaria/world_malaria_report_2010/worldmalariareport2010.pdf.
  2. Joint United Nations Programme on HIV/AIDS (UNAIDS), “Global report: UNAIDS report on the global AIDS epidemic,” 2010, http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf.
  3. N. French, J. Nakiyingi, E. Lugada, C. Watera, J. A. G. Whitworth, and C. F. Gilks, “Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults,” AIDS, vol. 15, no. 7, pp. 899–906, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Whitworth, D. Morgan, M. Quigley et al., “Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study,” Lancet, vol. 356, no. 9235, pp. 1051–1056, 2000. View at Google Scholar · View at Scopus
  5. World Health Organization, Guidelines for treatment of malaria, World Health Organization, 2006.
  6. World Health Organization, Guidelines for treatment of malaria, World Health Organization, 2nd edition, 2010.
  7. Federal Ministry of Health, “National Malaria Control Programme: Strategic Plan 2009–2013,” Abuja, Nigeria, 2008, http://nmcpnigeria.org/f/Nigeria%20Annex%201_National%20Malaria%20Control%20Strategic%20Plan%202009-2013.pdf.
  8. X. -Q. Li, A. Björkman, T. B. Andersson, L. L. Gustafsson, and C. M. Masimirembwa, “Identification of human cytochrome P450s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data,” European Journal of Clinical Pharmacology, vol. 59, no. 5-6, pp. 429–442, 2003. View at Publisher · View at Google Scholar
  9. K. F. Ilett, B. T. Ethell, J. L. Maggs et al., “Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases,” Drug Metabolism and Disposition, vol. 30, no. 9, pp. 1005–1012, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Benakis, M. Paris, L. Loutan, C. T. Plessas, and S. T. Plessas, “Pharmacokinetics of artemisinin and artesunate after oral administration in healthy volunteers,” American Journal of Tropical Medicine and Hygiene, vol. 56, no. 1, pp. 17–23, 1997. View at Google Scholar · View at Scopus
  11. P. Newton, Y. Suputtamongkol, P. Teja-Isavadharm et al., “Antimalarial bioavailability and disposition of artesunate in acute falciparum, malaria,” Antimicrobial Agents and Chemotherapy, vol. 44, no. 4, pp. 972–977, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. Q. Li, L. H. Xie, A. Haeberle, J. Zhang, and P. Weina, “The evaluation of radiolabeled artesunate on tissue distribution in rats and protein binding in humans,” American Journal of Tropical Medicine and Hygiene, vol. 75, no. 5, pp. 817–826, 2006. View at Google Scholar · View at Scopus
  13. S. H. Cheeseman, S. E. Hattox, M. M. McLaughlin et al., “Pharmacokinetics of nevirapine: Initial single-rising-dose study in humans,” Antimicrobial Agents and Chemotherapy, vol. 37, no. 2, pp. 178–182, 1993. View at Google Scholar · View at Scopus
  14. P. Riska, M. Lamson, T. Macgregor et al., “Disposition and biotransformation of the antiretroviral drug nevirapine in humans,” Drug Metabolism and Disposition, vol. 27, no. 8, pp. 895–901, 1999. View at Google Scholar · View at Scopus
  15. M. Lamson, T. MacGregor, P. Riska et al., “Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways,” Clinical Pharmacology and Therapeutics, vol. 65, no. 2, p. 137, 1999. View at Google Scholar · View at Scopus
  16. W. Hanpithakpong, B. Kamanikom, A. M. Dondorp et al., “A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma,” Journal of Chromatography B, vol. 876, no. 1, pp. 61–68, 2008. View at Publisher · View at Google Scholar
  17. T. Kredo, K. Mauff, J. S. Van Der Walt et al., “Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 12, pp. 5616–5623, 2011. View at Publisher · View at Google Scholar
  18. F. Ezzet and J. Karbwang, “Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients,” British Journal of Clinical Pharmacology, vol. 46, no. 6, pp. 553–561, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Price, M. Van Vugt, L. Phaipun et al., “Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives,” American Journal of Tropical Medicine and Hygiene, vol. 60, no. 4, pp. 547–555, 1999. View at Google Scholar · View at Scopus
  20. C. Orrell, F. Little, P. Smith et al., “Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers,” European Journal of Clinical Pharmacology, vol. 64, no. 7, pp. 683–690, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Teja-isavadharm, G. Watt, C. Eamsila et al., “Comparative pharmacokinetics and effect kinetics of orally administered artesunate in healthy volunteers and patients with uncomplicated falciparum malaria,” American Journal of Tropical Medicine and Hygiene, vol. 65, no. 6, pp. 717–721, 2001. View at Google Scholar · View at Scopus
  22. L. Dickinson, S. Khoo, and D. Back, “Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons,” Current Opinion in HIV and AIDS, vol. 3, no. 3, pp. 296–305, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. C. V. Fletcher, “Drug interactions should be evaluated in patients,” Clinical Pharmacology and Therapeutics, vol. 88, no. 5, pp. 585–587, 2010. View at Publisher · View at Google Scholar · View at Scopus